Perceptive Advisors LLC Solid Biosciences Inc. Transaction History

Perceptive Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $14 Million - $28 Million	2,608,695 Added 24.15%	13,412,552 $74.2 Million
Q4 2020 Feb 16, 2021	BUY	$3.08 - $7.79 $12.5 Million - $31.6 Million	4,054,054 Added 60.06%	10,803,857 $81.9 Million
Q2 2020 Aug 14, 2020	BUY	$2.1 - $3.42 $14.2 Million - $23.1 Million	6,749,803 New	6,749,803 $19.8 Million
Q4 2019 Feb 14, 2020	SELL	$2.82 - $12.9 $19 Million - $87.1 Million	-6,749,803 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.33 - $11.64 $12.2 Million - $32.9 Million	2,822,581 Added 71.87%	6,749,803 $69.8 Million
Q2 2019 Aug 14, 2019	BUY	$4.6 - $10.13 $18.1 Million - $39.8 Million	3,927,222 New	3,927,222 $22.6 Million
Q1 2019 May 15, 2019	SELL	$7.19 - $32.37 $28.2 Million - $127 Million	-3,927,222 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$21.32 - $46.34 $83.7 Million - $182 Million	3,927,222 New	3,927,222 $105 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.